"First-in-Patient Case Study of a Novel Nanosynthetic Bone Graft Substitute: OssDsign Catalyst™"

This case study describes the first use of a novel nanosynthetic bone graft, OssDsign™ Catalyst, in Spinal fusion patient. new graft consists nanoscale calcium phosphate containing silicate substitution (5.8wt% silicon) which has been shown to be capable regenerating via endochondral ossification route challenging animal models [1,2], resulting high rates at very early timepoints comparable existing synthetic grafts as well robust osteoconductive formation local graft.